6533b831fe1ef96bd1298f78

RESEARCH PRODUCT

Second-generation preimplantation genetic testing for aneuploidy in assisted reproduction: a SWOT analysis.

José BellverErnesto BoschJuan José EspinósFrancisco FabreguesJuan FontesJuan García-velascoJoaquín LlácerAntonio RequenaMiguel Angel ChecaSpanish Infertility Swot Group (Sisg)

subject

0301 basic medicineInfertilityPregnancy RateReproduction (economics)AneuploidyBlastocyst biopsy03 medical and health sciences0302 clinical medicinePregnancymedicineLive birthHumansIn patientGenetic TestingSWOT analysisPreimplantation DiagnosisGenetic testing030219 obstetrics & reproductive medicinePreimplantation genetic testingmedicine.diagnostic_testbusiness.industryAssisted reproductionObstetrics and Gynecologymedicine.diseaseAneuploidyImplantationAbortion Spontaneous030104 developmental biologyReproductive MedicineRisk analysis (engineering)InfertilityFemalebusinessLive birthDevelopmental Biology

description

Second-generation preimplantation genetic testing for aneuploidy (PGT-A 2.0) in patients with an unfavourable reproductive and IVF prognosis is becoming common practice, with the aim of improving reproductive outcomes. However, there is still no clear evidence on the possible advantages and drawbacks with regard to this procedure. In this discussion paper, based on a SWOT (strengths, weaknesses, opportunities, threats) analysis, the different aspects of this strategy are evaluated. Current evidence suggests that PGT-A 2.0 should not at present have an indiscriminate application, but it might be indicated in cases in which the risk of aneuploidy is increased.

yearjournalcountryeditionlanguage
2019-08-13
10.1016/j.rbmo.2019.07.037https://hdl.handle.net/10668/15433